IDEAYA Biosciences to Present Key Data on Darovasertib and IDE849 at ESMO 2026 — IDEAYA Biosciences, Inc.

Event summary

IDEAYA Biosciences will present three abstracts at ESMO 2026, including data from darovasertib trials in uveal melanoma and IDE849 trials in small cell lung carcinoma.
Presentations cover Phase 2/3 OptimUM-02 trial for HLA*A2:01-negative metastatic uveal melanoma, Phase 2 OptimUM-01 trial for HLA*A2:01-positive metastatic uveal melanoma, and Phase 2 OptimUM-09 neoadjuvant trial.
Hengrui Pharma will present long-term results from a Phase 1 study of IDE849 (SHR-4849) in relapsed small cell lung carcinoma and other neuroendocrine carcinomas.
IDEAYA aims to initiate the first registrational trial for IDE849 by year-end, targeting both China and the US markets.

The big picture

IDEAYA Biosciences is positioning itself as a key player in precision oncology, with a focus on synthetic lethality and antibody-drug conjugates. The upcoming ESMO presentations highlight the company's progress in developing targeted therapies for niche cancer indications, particularly uveal melanoma and small cell lung carcinoma. The strategic partnership with Hengrui Pharma underscores IDEAYA's global ambitions, as it seeks to expand its pipeline and commercialize innovative treatments.

What we're watching

Clinical Efficacy: How the upcoming data from darovasertib trials will impact its potential as a treatment option across the uveal melanoma patient journey.
Regulatory Pathway: Whether IDE849 can achieve best-in-class status in SCLC and NECs, given the planned initiation of registrational trials by year-end.
Market Expansion: The pace at which Hengrui Pharma can advance IDE849 in China while IDEAYA pursues parallel development in the US and other regions.